Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1624 1625 1657 1763
This examiner grants 67% of resolved cases
Luke Alan Boralsky, based in Tech Center 1700 and Art Unit 1600, has a limited history of 6 resolved cases. His allowance rate of 66.7% suggests a moderate level of grant activity, though the sample size is small. The interview lift of 44.4% is very high, indicating that interviews have been highly effective in the few cases he has handled. The median days to allowance is 1108, providing an initial look at his prosecution timeline.
With only 6 resolved cases, these metrics should be viewed as preliminary. The 66.7% allowance rate is a positive sign for patentability. The interview lift suggests a strong benefit to direct engagement. The 1108-day median serves as an early baseline for pendency. Practitioners should monitor how these trends develop in Art Unit 1600 as more cases are resolved, using this early data as a starting point for strategic planning and client communication.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18285019 | USE OF PSYCHEDELICS TO TREAT DEMENTIA | Non-Final OA | The University of British Columbia |
| 18571783 | METHOD FOR PRODUCING ALKYLENE OXIDES | Non-Final OA | Covestro Deutschland AG |
| 18372662 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18541015 | HSD17B13 Inhibitors and/or Degraders | Non-Final OA | Pfizer Inc. |
| 18717181 | METHODS OF ADMINISTERING A MODULATOR OF HEMOGLOBIN | Non-Final OA | Global Blood Therapeutics, Inc. |
| 18335415 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | Non-Final OA | Intervet Inc. |
| 18558595 | THIOEPOXY GROUP- AND (METH)ALLYL GROUP-CONTAINING COMPOUND, AND METHOD FOR PRODUCING SAME | Non-Final OA | Shin-Etsu Chemical Co., Ltd. |
| 18543655 | ISOMEROHYDROLASE INHIBITOR FOR TREATMENT OF ATROPHIC FORM OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | Non-Final OA | ARIBIO CO., LTD. |
| 18541289 | CRYSTALLINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Final Rejection | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | Non-Final OA | Durect Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy